Comparative Renal Effects of Dipeptidyl Peptidase-4 Inhibitors and Sodium-Glucose Cotransporter 2 Inhibitors on Individual Outcomes in Patients with Type 2 Diabetes: A Systematic Review and Network Meta-Analysis
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Bae, Jae Hyun | - |
dc.contributor.author | Park, Eun-Gee | - |
dc.contributor.author | Kim, Sunhee | - |
dc.contributor.author | Kim, Sin Gon | - |
dc.contributor.author | Hahn, Seokyung | - |
dc.contributor.author | Kim, Nam Hoon | - |
dc.date.accessioned | 2021-11-22T15:41:01Z | - |
dc.date.available | 2021-11-22T15:41:01Z | - |
dc.date.created | 2021-08-30 | - |
dc.date.issued | 2021-04 | - |
dc.identifier.issn | 2093-596X | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/128372 | - |
dc.description.abstract | Background: To compare the renal effects of dipeptidyl peptidase-4 (DPP-4) inhibitors and sodium-glucose cotransporter 2 (SGLT2) inhibitors on individual outcomes in patients with type 2 diabetes. Methods: We searched electronic databases (MEDLINE, Embase, and the Cochrane Central Register of Controlled Trials) from inception to June 2019 to identity eligible randomized controlled trials of DPP-4 inhibitors or SGLT2 inhibitors that reported at least one kidney outcome in patients with type 2 diabetes. Outcomes of interest were microalbuminuria, macroalbuminuria, worsening nephropathy, and end-stage kidney disease (ESKD). We performed an arm-based network meta-analysis using Bayesian methods and calculated absolute risks and rank probabilities of each treatment for the outcomes. Results: Seventeen studies with 87,263 patients were included. SGLT2 inhibitors significantly lowered the risks of individual kidney outcomes, including microalbuminuria (odds ratio [OR], 0.64; 95% credible interval [CrI], 0.41 to 0.93), macroalbuminuria (OR, 0.48; 95% CrI, 0.24 to 0.72), worsening nephropathy (OR, 0.65; 95% CrI, 0.44 to 0.91), and ESKD (OR, 0.65; 95% CrI, 0.46 to 0.98) as compared with placebo. However, DPP-4 inhibitors did not lower the risks. SGLT2 inhibitors were considerably associated with higher absolute risk reductions in all kidney outcomes than DPP-4 inhibitors, although the benefits were statistically insignificant. The rank probabilities showed that SGLT2 inhibitors were better treatments for lowering the risk of albuminuria and ESKD than placebo or DPP-4 inhibitors. Conclusion: SGLT2 inhibitors were superior to DPP-4 inhibitors in reducing the risk of albuminuria and ESKD in patients with type 2 diabetes. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | KOREAN ENDOCRINE SOC | - |
dc.subject | CHRONIC KIDNEY-DISEASE | - |
dc.subject | DOUBLE-BLIND | - |
dc.subject | CARDIOVASCULAR OUTCOMES | - |
dc.subject | RECEPTOR AGONISTS | - |
dc.subject | MORTALITY RISK | - |
dc.subject | GLP-1 RECEPTOR | - |
dc.subject | LONG-TERM | - |
dc.subject | DAPAGLIFLOZIN | - |
dc.subject | EFFICACY | - |
dc.subject | SAFETY | - |
dc.title | Comparative Renal Effects of Dipeptidyl Peptidase-4 Inhibitors and Sodium-Glucose Cotransporter 2 Inhibitors on Individual Outcomes in Patients with Type 2 Diabetes: A Systematic Review and Network Meta-Analysis | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Kim, Sin Gon | - |
dc.contributor.affiliatedAuthor | Kim, Nam Hoon | - |
dc.identifier.doi | 10.3803/EnM.2020.912 | - |
dc.identifier.scopusid | 2-s2.0-85105680324 | - |
dc.identifier.wosid | 000645563800018 | - |
dc.identifier.bibliographicCitation | ENDOCRINOLOGY AND METABOLISM, v.36, no.2, pp.388 - 400 | - |
dc.relation.isPartOf | ENDOCRINOLOGY AND METABOLISM | - |
dc.citation.title | ENDOCRINOLOGY AND METABOLISM | - |
dc.citation.volume | 36 | - |
dc.citation.number | 2 | - |
dc.citation.startPage | 388 | - |
dc.citation.endPage | 400 | - |
dc.type.rims | ART | - |
dc.type.docType | Review | - |
dc.identifier.kciid | ART002710861 | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
dc.relation.journalResearchArea | Endocrinology & Metabolism | - |
dc.relation.journalWebOfScienceCategory | Endocrinology & Metabolism | - |
dc.subject.keywordPlus | CHRONIC KIDNEY-DISEASE | - |
dc.subject.keywordPlus | DOUBLE-BLIND | - |
dc.subject.keywordPlus | CARDIOVASCULAR OUTCOMES | - |
dc.subject.keywordPlus | RECEPTOR AGONISTS | - |
dc.subject.keywordPlus | MORTALITY RISK | - |
dc.subject.keywordPlus | GLP-1 RECEPTOR | - |
dc.subject.keywordPlus | LONG-TERM | - |
dc.subject.keywordPlus | DAPAGLIFLOZIN | - |
dc.subject.keywordPlus | EFFICACY | - |
dc.subject.keywordPlus | SAFETY | - |
dc.subject.keywordAuthor | Albuminuria | - |
dc.subject.keywordAuthor | Diabetes mellitus, type 2 | - |
dc.subject.keywordAuthor | Diabetic nephropathies | - |
dc.subject.keywordAuthor | Dipeptidyl-peptidase IV inhibitors | - |
dc.subject.keywordAuthor | Kidney failure, chronic | - |
dc.subject.keywordAuthor | Network meta-analysis | - |
dc.subject.keywordAuthor | Sodium-glucose transporter 2 inhibitors | - |
dc.subject.keywordAuthor | Systematic review | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
145 Anam-ro, Seongbuk-gu, Seoul, 02841, Korea+82-2-3290-2963
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.